<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510688</url>
  </required_header>
  <id_info>
    <org_study_id>SOGUG-2017-A-IEC(REN)-7</org_study_id>
    <nct_id>NCT04510688</nct_id>
  </id_info>
  <brief_title>Spanish Real-World Evidence Cabozantinib</brief_title>
  <acronym>SRWEC</acronym>
  <official_title>Study of the Effectiveness and Safety of Cabozantinib Treatment in Patients With Advanced Renal Cell Carcinoma (RCC) Under a Spanish Managed Access Program and Real-world Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCC (Renal Cell Carcinoma) is the most common form of kidney cancer, accounting for 2-3% of&#xD;
      all adult malignancies and for 90% of all kidney cancers. The incidence of RCC has steadily&#xD;
      increased over the past two decades, showing a plateau in recent years. Many patients with&#xD;
      RCC remain asymptomatic until late disease stages and other patients have disease at&#xD;
      diagnosis (metastatic RCC or mRCC).&#xD;
&#xD;
      Recently, the tyrosine kinase inhibitor (TKI) cabozantinib was approved as a first-line&#xD;
      therapy for patients with advanced clear-cell RCC (ccRCC). Cabozantinib was initially&#xD;
      approved for patients previously treated with antiangiogenic therapy based on the phase 3&#xD;
      METEOR study, which demonstrated a clinical benefit compared with everolimus.&#xD;
&#xD;
      Immunotherapy has been also developed in ccRCC.&#xD;
&#xD;
      The frontline treatment paradigm for ccRCC has evolved, particularly for&#xD;
      intermediate-/poor-risk patients, with the recent addition of cabozantinib and&#xD;
      nivolumab/ipilimumab (immunotherapy), but overall survival data are needed to understand&#xD;
      their benefit-to-risk profiles compared with established therapies.&#xD;
&#xD;
      In October 2016, the Spanish Agency of medicines (AEMPS) granted the temporary Authorization&#xD;
      for special use to Cabometyx® 20/40/60 mg within a Managed Access Program (MAP) for the&#xD;
      treatment of advanced RCC in adults following prior VEGF-targeted therapy (Vascular&#xD;
      Endothelial Growth Factor targeted therapy). The MAP allows the possibility of using a&#xD;
      medicinal product which is not yet commercially available or approved. By the end of the MAP&#xD;
      period, on July 2017, 136 patients had been included by 61 centers who received at least one&#xD;
      dose of Cabometyx® for the treatment of advanced RCC.&#xD;
&#xD;
      Since then, Cabometyx® 20/40/60 mg was made commercially available for the treatment of&#xD;
      advanced RCC in adults following prior VEGF-targeted therapy. After the commercialization of&#xD;
      Cabometyx® in July 2017 in Spain, the inclusion of new patients in the MAP was closed but&#xD;
      those patients that were already included continued receiving Cabometyx® free of charge until&#xD;
      clinical decision. In July 2018, the European Commission approved a new indication for adult&#xD;
      patients previously untreated with intermediate or poor risk.&#xD;
&#xD;
      Based on this rationale, the aim of this study is to obtain safety and effectiveness&#xD;
      information regarding the use of cabozantinib in a non-selected RCC population, both in&#xD;
      patients that received this agent under the MAP or under routine clinical prescription&#xD;
      (real-world [RW]).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness: Progression-Free Survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Evaluation of the effectiveness of cabozantinib in terms of investigator-assessed PFS (Progression-Free Survival) based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Reactions</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Evaluation of the safety of cabozantinib by recording the incidence of adverse reactions in both MAP and RW cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose reductions</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Evaluation of the safety of cabozantinib by recording the incidence of dose reductions in both MAP and RW cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of temporary interruptions or discontinuations</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Evaluation of the safety of cabozantinib by recording the Incidence of temporary interruptions or discontinuations in both MAP and RW cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of use of medications to manage adverse reactions</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Evaluation of the safety of cabozantinib by recording the incidence of use of medications to manage adverse reactions in both MAP and RW cohorts.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Managed Access Program (MAP) patients</arm_group_label>
    <description>Patients with RCC treated with cabozantinib under a Managed Access Program (MAP) prior to Cabometyx® marketing authorization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Real World (RW) patients</arm_group_label>
    <description>Patients with RCC treated with cabozantinib as routine clinical prescription (Real World), with treatment started after Cabometyx® marketing authorization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Observation of treatment with Cabozantinib</description>
    <arm_group_label>Managed Access Program (MAP) patients</arm_group_label>
    <arm_group_label>Real World (RW) patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data from patients with Renal Cell Carcinoma (RCC) currently under tretament at the study&#xD;
        site or data from deceased patients with RCC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females, aged 18 years or older.&#xD;
&#xD;
          2. Diagnosis of advanced Renal Cell Carcinoma (RCC)&#xD;
&#xD;
          3. Alive or dead patients at study initiation who received at least one dose of&#xD;
             cabozantinib for the treatment of RCC between October 2016 and 1 st June 2019.&#xD;
&#xD;
          4. Alive patients who agree to participate and signed the Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who decline consent.&#xD;
&#xD;
          2. Patients whose hospital medical records are unavailable for review.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Suárez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Grau Miró</last_name>
    <phone>+34 610 286 915</phone>
    <email>trialmanager@sogug.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María José Méndez Vidal, MD</last_name>
    </contact>
    <investigator>
      <last_name>María José Méndez Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco José Álvarez Márquez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco José Álvarez Márquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <state>Andalucía</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Martínez Ortega, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esther Martínez Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Álvarez Fernández, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Álvarez Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gallardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Gallardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Rodríguez Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ángel Rodríguez Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgia Anguera Palacios, MD</last_name>
    </contact>
    <investigator>
      <last_name>Georgia Anguera Palacios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Catalunya</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María José Miranda, MD</last_name>
    </contact>
    <investigator>
      <last_name>María José Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Catalunya</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gallardo Díaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Gallardo Díaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regina Gironés Sarrió, MD</last_name>
    </contact>
    <investigator>
      <last_name>Regina Gironés Sarrió, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valenica</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Chirivella González, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabel Chirivella González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Molins Palau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmen Molins Palau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <state>Extremadura</state>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Delgado Mingorance, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Delgado Mingorance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Medina Colmenero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Medina Colmenero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ferrol</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Alfonso Alfonso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Alfonso Alfonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovidio Fernández Calvo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ovidio Fernández Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Ballears</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Garcías de España, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmen Garcías de España, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Belén González, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Belén González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Unviersitario de Gran Canaria Doctor Negrin</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saray Galván Ruiz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saray Galván Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolina Hernández Pérez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carolina Hernández Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo Rodríguez Vida, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alejo Rodriguez Vida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Suárez Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Suárez Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Reig Torras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oscar Reig Torras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Crespo Herrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillermo Crespo Herrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Munarriz Ferrandis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Munarriz Ferrandis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa Guzmán</last_name>
    </contact>
    <investigator>
      <last_name>Jose Carlos Villa Guzmán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Collado Martín, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Collado Martín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Fernández Núñez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fernández Núñez Fernández Núñez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iciar García Carbonero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Iciar García Carbonero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria José Juan Fita, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria José Juan Fita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José García Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>José García Sánchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martín Lázaro Quintela, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martín Lázaro Quintela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

